US 12,145,913 B2
Inhibition of Olig2 activity
Graham Beaton, San Diego, CA (US); Stanton F. McHardy, Waring, TX (US); Ambrosio Lopez, Jr., San Antonio, TX (US); Bismarck Campos, San Antonio, TX (US); and Hua-Yu Leo Wang, San Antonio, TX (US)
Assigned to CURTANA PHARMACEUTICALS, INC., Austin, TX (US)
Filed by Curtana Pharmaceuticals, Inc., Austin, TX (US)
Filed on Apr. 19, 2021, as Appl. No. 17/234,332.
Application 17/234,332 is a continuation of application No. 16/328,551, granted, now 11,242,323, previously published as PCT/US2017/048716, filed on Aug. 25, 2017.
Claims priority of provisional application 62/380,281, filed on Aug. 26, 2016.
Prior Publication US 2021/0253535 A1, Aug. 19, 2021
Int. Cl. C07D 239/48 (2006.01); A61P 35/00 (2006.01); C07D 401/12 (2006.01); C07D 403/12 (2006.01); C07D 405/12 (2006.01)
CPC C07D 239/48 (2013.01) [A61P 35/00 (2018.01); C07D 401/12 (2013.01); C07D 403/12 (2013.01); C07D 405/12 (2013.01)] 6 Claims
 
1. A compound having the structure of:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt or solvate thereof.